Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea

Open access
Brenner, Darren M., Sayuk, Gregory S. · 2020 · Advances in Therapy

Abstract

Irritable bowel syndrome (IBS) is a functional bowel disorder characterized by abdominal pain and alterations in stool form and/or frequency, leading to reduced quality of life. Pharmacologic agents currently approved by the US Food and Drug Administration for treatment of IBS with diarrhea (IBS-D) in adults are the nonsystemic antibiotic rifaximin, the mixed µ- and κ-opioid receptor agonist/δ-opioid antagonist eluxadoline, and the selective serotonin 5-HT 3 antagonist alosetron (the last of which is indicated only in women with severe IBS-D refractory to conventional therapy). Both eluxadoline and alosetron are administered as chronic daily therapies; rifaximin is given as a 2-week course of treatment with repeat courses administered as needed for symptom recurrence. Presumed mechanisms of action of rifaximin include modulation of the gut microbiota, anti-inflammatory activity, normalization of visceral hypersensitivity, and reduction in intestinal permeability. Eluxadoline targets opioid receptors in the gastrointestinal (GI) tract, resulting in decreased GI motility, fluid secretion, and visceral pain perception. Alosetron antagonizes serotonergic afferent neural signals and also slows GI motility. The efficacy and safety of these agents have been investigated in several rigorous clinical trials, and it has been demonstrated that they improve global and individual IBS symptoms. This review highlights the pivotal efficacy and safety data of the three pharmacologic agents currently indicated in the USA for the management of IBS-D in adults. Funding : Salix Pharmaceuticals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-019-01116-z

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 55

Metadata

Authors
Brenner, D. M., & Sayuk, G. S.
Affiliations
  • Northwestern University (US)
  • Washington University in St. Louis (US)
Corresponding author
Brenner, Darren M.
Venue
Advances in Therapy
Published
2019-11-09
Volume
37
Issue
1
Pages
83-96
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W2985697236
Cited by
55
References
34
Citations by year
2026: 3 · 2025: 7 · 2024: 13 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 6
FWCI
1.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Advances in Therapy (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Salix Pharmaceuticals (Funding for technical editorial, medical writing support. Salix Pharmaceuticals also provided funding for this article to be published for open access.)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
irritable bowel syndrome with diarrhea, diarrhea-predominant irritable bowel syndrome, rifaximin, eluxadoline, alosetron, opioid agonists, 5-HT3 receptor antagonists, gut microbiota, visceral hypersensitivity, intestinal permeability, gastrointestinal motility, drug safety and efficacy, FDA-approved therapies
MeSH terms
Rifaximin, Adult, Carbolines, Diarrhea, Female, Gastrointestinal Agents, Humans, Imidazoles, Phenylalanine, Quality of Life, United States, United States Food and Drug Administration, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. https://app.cochat.ai/papers/10.1007/s12325-019-01116-z
The paper
Brenner, D. M., & Sayuk, G. S. (2020). Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea. Advances in Therapy. https://doi.org/10.1007/s12325-019-01116-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.